Celemics, Inc.

As of June 30, 2026, Celemics, Inc. carries a market capitalization of 133.84B, placing it among publicly traded companies globally. Its enterprise value stands at 111.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Celemics, Inc. has 11.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 19.65, and the price-to-book ratio stands at 4.40.

These figures are as of June 30, 2026. The EV/Sales ratio of 21.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 111.94B versus a market cap of 133.84B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Celemics, Inc. maintains a current ratio of 22.92, meaning it holds 22.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.49, indicating elevated leverage, while an interest coverage ratio of -7.30 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Celemics, Inc. posted a negative return on equity (ROE) of -51.97, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.41, reflecting losses generated across the asset base. The company generates approximately 126.55M in revenue per employee across its workforce of 41.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.18 indicates how many times Celemics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Celemics, Inc.'s stock has gained approximately 229.92% over the past 52 weeks. The 50-day moving average sits at 11,043.80, while the 200-day moving average is 10,084.43.

Over the twelve months ended June 30, 2026, Celemics, Inc. generated 5.22B in revenue and converted that into -13.62B in net income, yielding earnings per share of -1,589.54. EBITDA reached -3.21B, while operating income came in at -3.88B.

As of June 30, 2026, Celemics, Inc. holds 38.77B in cash and equivalents against 16.87B in total debt, resulting in a net debt position of -20.86B. Total book value stands at 30.39B, with working capital of 39.58B providing operational flexibility.

Celemics, Inc. produced -3.45B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -107.45M in capital expenditures, free cash flow totaled -3.56B - equivalent to -415.35 per share.

Over the twelve months ended June 30, 2026, Celemics, Inc. posted a gross margin of 42.79, reflecting its pricing power and cost economics. The operating margin of -74.41 and net profit margin of -260.90 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.58, meaning Celemics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Celemics, Inc. has an Altman Z-Score of 3.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.